Macrogenics Inc. (MGNX)
IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholder Rights Advocates at Levi & Korsinsky Investigate MacroGenics, Inc. (MGNX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MacroGenics, Inc. Being Investigated on Behalf of MacroGenics, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Natixis Advisors L.P. Invests $297,000 in MacroGenics, Inc. (NASDAQ:MGNX)
Natixis Advisors L.P. bought a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,892 shares of the biopharmaceutical company’s stock, valued at approximately $297,000. Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in shares of MacroGenics by 349.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,174 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 5,577 shares during the period. SG Americas Securities LLC purchased a new position in shares of MacroGenics during the third quarter worth approximately $97,000. Sherbrooke Park Advisers LLC purchased a new position in shares of MacroGenics during the third quarter worth approximately $99,000. WINTON GROUP Ltd bought a new position in shares of MacroGenics during the third quarter valued at approximately $147,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of MacroGenics during the third quarter valued at approximately $281,000. 96.89% of the stock is owned by hedge funds and other institutional investors. MacroGenics Stock Down 14.8 % Shares of MGNX opened at $4.36 on Monday. The company has a market cap of $273.07 million, a price-to-earnings ratio of -11.19 and a beta of 2.09. MacroGenics, Inc. has a twelve month low of $3.14 and a twelve month high of $21.88. The company has a 50 day moving average of $14.44 and a two-hundred day moving average of $12.70. MacroGenics (NASDAQ:MGNX – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.17). The company had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $13.63 million. MacroGenics had a negative return on equity of 98.01% and a negative net margin of 53.60%. On average, sell-side analysts expect that MacroGenics, Inc. will post -3.04 EPS for the current year. Insiders Place Their Bets In other MacroGenics news, VP Jeffrey Stuart Peters sold 51,395 shares of the firm’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.55, for a total value of $799,192.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.30% of the company’s stock. Wall Street Analyst Weigh In A number of equities analysts have recently issued reports on MGNX shares. JMP Securities dropped their price objective on shares of MacroGenics from $22.00 to $16.00 and set a “market outperform” rating on the stock in a research note on Friday, May 10th. HC Wainwright dropped their price objective on shares of MacroGenics from $16.00 to $4.00 and set a “neutral” rating on the stock in a research note on Monday, May 13th. Barclays dropped their price objective on shares of MacroGenics from $25.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. B. Riley started coverage on shares of MacroGenics in a research note on Friday, April 26th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, TD Cowen downgraded shares of MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $13.67. View Our Latest Stock Report on MacroGenics MacroGenics Company Profile (Free Report) MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
